DOI: 10.1055/s-00033990

TH Open

References

Peyvandi F, Scully M, Kremer Hovinga JA. , et al.
Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.

J Thromb Haemost 2017;
15 (07) 1448-1452

Download Bibliographical Data

Access:
Access:
Access: